$26.10
1.174.69%
Last update: Oct 20, 5:00 PM
$26.10
1.174.69%

Nurix Therapeutics (NRIX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $3.98 | $-0.72 | $-0.76 | $-0.89 |
| Actual | $4.73 | $-0.81 | $-0.79 | $-0.82 |
| Surprise | +18.8% | -12.5% | -3.95% | +7.87% |
| Revenue | ||||
| Estimate | $411.5M | $15.1M | $14.4M | $15.2M |
| Actual | $673.1M | $9.0M | $6.3M | $13.6M |
| Surprise | +63.6% | -40.1% | -56.5% | -10.7% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.10 | $-0.55 | $-0.45 | $-0.40 |
| Revenue | ||||
| Consensus | $234.6M | $18.2M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 12, 2026 | $4.73 | $3.98 | 18.8 % |
| Q2 | Jul 9, 2026 | $-0.81 | $-0.72 | -12.5 % |
| Q1 | Apr 8, 2026 | $-0.79 | $-0.76 | -3.95 % |
| Q4 | Jan 28, 2026 | $-0.82 | $-0.89 | 7.87 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 12, 2026 | $673.06M | $411.48M | 63.6 % |
| Q2 | Jul 9, 2026 | $9.04M | $15.09M | -40.1 % |
| Q1 | Apr 8, 2026 | $6.25M | $14.39M | -56.5 % |
| Q4 | Jan 28, 2026 | $13.58M | $15.20M | -10.7 % |